Optimizing real-world benefit and risk of new psychedelic medications: the need for innovative postmarket surveillance

Psychedelic drugs constitute a chemically heterogeneous group that alter behaviour, mood, thought and perception; the term is used in this Perspective to encompass serotonergic, entactogenic and dissociative substances. Black and colleagues note that while some compounds have long historical use and others are newly developed by industry or illicit synthesis, regulatory classifications (for example US Schedule 1) have been shifting alongside a growing international research effort. Late-stage clinical trials have reported positive results for indications such as major depressive disorder, treatment-resistant depression (psilocybin) and post-traumatic stress disorder (MDMA), and an MDMA new drug application has been submitted to the US FDA, but the FDA has issued draft trial guidance without parallel guidance for postmarket surveillance. This paper sets out to define the surveillance needs specific to psychedelic medications as they move into real-world clinical use. The authors argue that existing surveillance systems are poorly matched to the distinctive pharmacology, care models and socio-environmental influences surrounding psychedelic-assisted psychotherapy, and they propose a purpose-built, multi-component ‘‘mosaic’’ of data systems and measurement approaches to monitor real-world effectiveness, safety and equitable access.

The extracted text does not report a formal methods section typical of empirical research; instead, Black and colleagues present a narrative synthesis and Perspective. They draw on findings from late-phase clinical trials, pharmacovigilance experience (for example with esketamine), epidemiologic examples (coding and misclassification problems in cannabis and synthetic-opioid data) and published incidence estimates to identify gaps and propose a surveillance framework. The argument is built by integrating evidence about adverse events, effectiveness, treatment settings and regulatory practice, and by outlining the data elements and system characteristics needed to monitor outcomes across diverse real-world settings. Because this is a conceptual and policy-oriented paper rather than an original dataset analysis, there is no description of participant recruitment, randomisation, statistical modelling or risk-of-bias assessment. Instead, the methods consist of critical synthesis and generation of recommendations for surveillance design, measurement harmonisation and data-system architecture.

Black and colleagues identify multiple interrelated domains that postmarket surveillance for psychedelic medications must cover, arguing that conventional drug-monitoring systems will be insufficient and may produce misleading signals. They emphasise three overarching needs: capture of real-world effectiveness, precise attribution of intended psychoactive effects versus adverse events (AEs), and monitoring of the full continuum of use from supervised therapy to illicit or unsupervised administration. On real-world effectiveness, the authors stress that trial-proven efficacy may not generalise to broader, more medically and psychiatrically complex populations. They recommend incorporating validated symptom measures and patient-perceived effectiveness into surveillance, noting that perceptions may influence behaviour such as dose escalation or seeking illicit products. Measurement challenges include dose variability, setting, social determinants and the presence or absence of a facilitator or therapist. Disaggregation of intended psychoactive effects from unintended harms is highlighted as a particular difficulty. The paper describes a severity spectrum—from transient, intended perceptual effects to persistent phenomena (for example flashbacks or hallucinogen-persisting perception disorder) and possible progression to psychotic-spectrum illness in susceptible individuals. The authors cite several quantitative observations: dissociative reactions occurred in 23% of adults with treatment-resistant depression who received esketamine; in a phase 1 trial 25 mg of psilocybin produced hallucinations in 67% of healthy participants and flashbacks in 8.3%. They underline that unexpected risks are likely to emerge as use expands to more diverse populations. Non-psychoactive adverse effects also warrant active surveillance, with nausea and vomiting being most common and cardiovascular effects—hypertension, tachycardia and arrhythmias—potentially important in susceptible patients. The paper notes rare but serious outcomes (for example intracranial haemorrhage secondary to hypertensive episodes) may only be detected at the population level. Comorbidity and polypharmacy add unpredictability to risk profiles. Examples supplied include interactions between esketamine and stimulants increasing cardiac risk, and the theoretical but uncommon risk of serotonin toxicity when psychedelics are combined with other serotonergic agents. The authors recommend surveillance capture of concomitant prescription and illicit drug use, pharmacogenetic variants that may alter pharmacokinetics or pharmacodynamics, and the broader medical and psychiatric history of treated patients. Motivation for use—medical, spiritual or recreational—is put forward as a key modifier of safety and effectiveness. The investigators warn against simplistic classifications of ‘‘misuse’’ that could propagate stigma and hamper access; instead they argue for measurement of motive and the subject’s ‘‘set’’ (mental state before treatment) because these factors plausibly influence outcomes. The role of facilitators and psychotherapy is described as a central effect modifier. Clinical trials typically used licensed psychiatrists and structured psychologic support, whereas community provision may include a wide range of facilitator training and settings (including minimal training under state programmes). This variability is likely to affect both safety and effectiveness and to produce inequities driven by cost and structural factors. The authors also stress the need to monitor serious harms related to provider misconduct, including sexual abuse, and note that patient-reported data collected outside provider settings will be important because facilitators may be disinclined to report such events. Practical challenges for real-world analyses are enumerated: no single data source will suffice, harmonisation of measurements is essential, and product-specific identification is required to avoid exposure misclassification. The authors present examples where coding conflated exposures—only 25% of hospital visits with cannabis-related ICD codes were actually attributable to cannabis, and synthetic-opioid mortality coding can mask non-fentanyl agents. They recommend repeated measures (for example ecological momentary assessment), instrument validation, triangulation across provider and patient reports, small-area estimation for local surveillance needs, and qualitative work to align measures with patient priorities. Finally, the paper outlines data-system needs: a mosaic of modified existing systems and purpose-built registries able to capture dose, product identity, treatment context, facilitator characteristics, concomitant medications and patient-reported outcomes. The authors propose validating behavioural and symptom scales for self-report, prospectively capturing product-specific information to avoid misattribution, and building trust with providers and marginalised communities to enable accurate data collection. They reference a study reporting that 33.2% of people with bipolar disorder self-reported symptom increases after psilocybin, using that example to underscore the importance of subpopulation analyses.

Black and colleagues conclude that surveillance for psychedelic medications must be flexible, collaborative and rigorous to ensure evidence-based policy and to protect patients. They propose a surveillance paradigm composed of multiple, harmonised data systems and standardised measures that together can support regulatory, clinical and public-health decision-making. The authors warn that failure to design fit-for-purpose surveillance risks both patient safety and the loss of therapeutic benefit, and they argue that many of their recommendations are achievable through epidemiologic study designs without mandatory reporting. Finally, they call for extensive collaboration, iterative validation and partnership among study teams, regulators, providers and patients to build a system that meets both federal and state evidence needs while minimising fragmentation and burdens on stakeholders.